{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-26-000033","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.813675+00:00","generated_at":"2026-05-14T23:28:04.439191+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zentalis first patient dosed in Phase 3 ASPENOVA trial for azenosertib in Cyclin E1+ PROC","bullets":["Phase 3 ASPENOVA compares azenosertib 400mg QD 5:2 to standard-of-care chemo in ~420 Cyclin E1+ platinum-resistant ovarian cancer patients.","Trial designed as confirmatory study to support full approval, with DENALI Part 2 topline expected by year-end 2026 for accelerated approval path.","400mg QD 5:2 dose selected based on DENALI Part 2a interim analysis showing differentiated response rate over 300mg with comparable safety.","Collaborators include GOG Foundation, ENGOT, and APGOT; trial identifier NCT07546500."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-26-000033","json":"https://secwatch.observer/filing/0001725160-26-000033.json","markdown":"https://secwatch.observer/filing/0001725160-26-000033.md","text":"https://secwatch.observer/filing/0001725160-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000033/0001725160-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000033/zntl-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:28:04.439191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}